Yohimnine hcl
Reading File
Finding Sources
Searching the Web
yohimbine HCl pharmacology mechanism of action clinical uses 2025
Searching PubMed
yohimbine alpha-2 adrenergic receptor
Reading File
Reading File
I now have comprehensive information from authoritative sources. Here is the full profile:
Yohimbine HCl
Overview
Yohimbine hydrochloride is the water-soluble salt form of yohimbine, a naturally occurring indolealkylamine alkaloid. It is found in the bark of the West African tree Pausinystalia yohimbe and in Rauwolfia serpentina. Its chemical structure resembles reserpine. Trade names include Yocon, Yohimex, and Aphrodyne.
Mechanism of Action
Primary mechanism: Selective competitive antagonist at alpha-2 (alpha-2) adrenergic receptors. It has higher affinity for presynaptic alpha-2 receptors than postsynaptic ones. The binding affinities among alpha-2 subtypes are: alpha-2C (0.88 nM) > alpha-2A (1.4 nM) > alpha-2B (7.1 nM).
By blocking alpha-2 receptors, yohimbine removes the inhibitory feedback on norepinephrine release, leading to:
- Increased plasma norepinephrine levels in the synaptic cleft
- Enhanced sympathetic nervous system activity
Secondary receptor activity:
- Moderate affinity for alpha-1 adrenergic, dopamine D2, 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT2B receptors
- Behaves as an antagonist at alpha-1, alpha-2, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and dopamine D2 receptors
- Partial agonist at 5-HT1A
- Also antagonizes 5-HT effects (Goodman & Gilman)
- Anti-inflammatory properties via suppression of the NF-kB pathway (reduces IL-1beta, IL-6)
The net clinical result is increased parasympathetic (cholinergic) tone alongside enhanced sympathomimetic activity. - Kaplan & Sadock's Synopsis of Psychiatry
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | Erratic oral absorption; bioavailability 7-87% |
| Metabolism | Extensive hepatic first-pass metabolism |
| Half-life | 0.5 to 2 hours |
| CNS penetration | Readily enters the CNS |
Therapeutic Indications
1. Erectile Dysfunction (ED)
- Historically used for both idiopathic and medication-induced ED
- Mechanism: alpha-2 blockade leads to vasodilation in penile tissue, increasing penile blood inflow and decreasing outflow, plus cholinergic tone promotes erection
- Modestly beneficial over placebo, particularly in psychogenic ED
- However, PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) are now significantly more efficacious and are the preferred first-line agents
- Kaplan & Sadock's Synopsis, p. 2133
2. SSRI-Induced Sexual Dysfunction
- Reported to help counteract loss of sexual desire and orgasmic inhibition caused by SSRIs
- Not found effective in women for these indications
3. Other investigated uses:
- Diabetic neuropathy (some positive data)
- Postural (orthostatic) hypotension treatment
- Fat loss / weight management (off-label, stimulant-based mechanism increasing lipolysis via norepinephrine)
- Veterinary medicine: approved for reversal of xylazine anesthesia in animals
4. Research tool:
- Used as a pharmacological stressor to model anxiety and panic in research settings
- Precipitates panic attacks in patients with panic disorder but not in healthy subjects
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Adverse Effects
| System | Side Effects |
|---|---|
| Cardiovascular | Elevated BP, elevated heart rate, palpitations, chest pain |
| CNS | Anxiety, irritability, tremor, headache, dizziness, insomnia, increased psychomotor activity |
| GI | Nausea, vomiting |
| Skin | Flushing, sweating |
| Urinary | Urinary frequency |
Special risk - Panic Disorder: Patients with panic disorder show heightened sensitivity - they experience increased anxiety, elevated BP, and elevated plasma MHPG (3-methoxy-4-hydroxyphenylglycol, a norepinephrine metabolite). - Kaplan & Sadock's Synopsis of Psychiatry
Contraindications / Precautions
Yohimbine should NOT be used in patients with:
- Renal disease
- Cardiac disease
- Glaucoma
- History of gastric or duodenal ulcers
Use with caution in female patients and in psychiatric patients (may worsen mental status).
Drug Interactions
- Alpha-2 agonists (clonidine, guanfacine): Yohimbine blocks their effects - mutual pharmacodynamic antagonism
- Antidepressants (MAOIs, tricyclics): Additive sympathomimetic effects; increased risk of hypertensive crisis
- Stimulants: Additive cardiovascular risk
Dosage and Available Forms
- Available as 5.4 mg tablets
- Standard dose for ED: approximately 16 mg/day in divided doses of 2.7-5.4 mg three times daily
- If adverse effects occur: reduce dose first, then re-titrate gradually
- Kaplan & Sadock's Synopsis of Psychiatry, p. 2134
Regulatory Status
- In the US: can be legally sold as a dietary supplement (OTC)
- Prescription labeling for ED exists (Yocon)
- Claims of aphrodisiac effects or sexual performance enhancement on supplement labels are prohibited by the FDA
- Approved as a prescription drug in veterinary medicine (xylazine reversal)
Key Clinical Takeaways
- Yohimbine is an alpha-2 antagonist - it raises norepinephrine and has stimulant/sympathomimetic effects
- It is no longer a first-line agent for ED; PDE-5 inhibitors have replaced it
- Its use is controversial given inconsistent evidence and a significant side-effect profile
- It is dangerous in panic disorder, cardiac disease, and renal disease
- Its fat-burning claims are physiologically plausible (norepinephrine-driven lipolysis) but clinical evidence is limited
Recent literature (2024): Two reviews published in 2024 - Nowacka et al. (PMID 39684567) in Int J Mol Sci and Porrill et al. (PMID 39728757) in Neurology International - provide updated perspectives on yohimbine's multifaceted pharmacology, including its ergogenic and sympathomimetic properties, but neither overturns the established clinical picture.
This is a shared conversation. Sign in to Orris to start your own chat.